Endocrine Pharmacology Practice Questions

Q: A 50-year-old male with type 2 diabetes is prescribed a new medication to manage his condition. Which drug reduces postprandial hyperglycemia without increasing insulin levels?

Voglibose. ***Voglibose*** - **Voglibose** is an alpha-glucosidase inhibitor that works by delaying the digestion and absorption of carbohydrates in the small intestine. - This mechanism specifically reduces the postprandial rise in blood glucose without directly affecting insulin secretion or sensitivity. *Metformin* - **Metformin** primarily reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. - It does not specifically target postprandial hyperglycemia by delaying carbohydrate absorption to the extent that alpha-glucosidase inhibitors do, nor does it increase insulin levels. *Glibenclamide* - **Glibenclamide** is a sulfonylurea that stimulates insulin release from pancreatic beta cells. - This mechanism directly increases insulin levels, which is contrary to the question's premise. *Pioglitazone* - **Pioglitazone** is a thiazolidinedione (TZD) that improves insulin sensitivity in adipose tissue, muscle, and liver. - While it helps manage blood glucose, its primary action is not to reduce postprandial hyperglycemia without altering insulin levels; rather, it improves the body's response to existing insulin.

Q: Evaluate the reasons why metformin is contraindicated in patients with severe renal impairment.

Risk of lactic acidosis. ***Risk of lactic acidosis*** - Metformin is primarily excreted unchanged by the **kidneys**. In severe renal impairment, its accumulation leads to elevated plasma levels. - This accumulation inhibits **hepatic gluconeogenesis** and impairs lactate metabolism, significantly increasing the risk of **lactic acidosis**, a severe metabolic complication. *Potential for reduced drug efficacy in patients with renal impairment.* - Metformin's glucose-lowering efficacy is generally maintained or even enhanced in patients with mild to moderate renal impairment due to reduced clearance. - Reduced efficacy is not the primary concern; rather, it is the increased risk of accumulation and adverse effects. *Increased risk of hypoglycemia* - Metformin itself rarely causes **hypoglycemia** as it primarily works by reducing **hepatic glucose production** and improving insulin sensitivity, not by promoting insulin secretion. - The risk of hypoglycemia is mainly associated with other antidiabetic agents (e.g., sulfonylureas, insulin) or in situations of inadequate caloric intake. *Potential for liver toxicity* - Metformin is not known to cause significant **liver toxicity**; it is primarily metabolized by the kidneys. - Liver dysfunction could potentially impact lactate metabolism, but direct hepatotoxicity is not a primary contraindication for its use in renal impairment.

Q: Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Metformin. ***Metformin (Correct)*** - **Metformin** is a biguanide that primarily lowers blood glucose by activating **AMP-activated protein kinase (AMPK)**. - This activation improves **insulin sensitivity**, reduces hepatic glucose production, and decreases intestinal glucose absorption. - Metformin is the first-line oral agent for type 2 diabetes and works through AMPK-dependent mechanisms. *Glibenclamide (Incorrect)* - **Glibenclamide** is a sulfonylurea that stimulates insulin secretion from beta cells by blocking **ATP-sensitive potassium channels**. - It does not primarily improve **insulin sensitivity** or activate AMPK. - It works by increasing insulin release, not improving insulin action. *Pioglitazone (Incorrect)* - **Pioglitazone** is a thiazolidinedione (TZD) that improves **insulin sensitivity** by activating **peroxisome proliferator-activated receptor-gamma (PPAR-γ)** in adipose tissue. - While it enhances insulin sensitivity, its mechanism of action is distinct from AMPK activation. - This is an important distractor as it also improves insulin sensitivity but through a different pathway. *Acarbose (Incorrect)* - **Acarbose** is an alpha-glucosidase inhibitor that reduces post-prandial glucose levels by delaying carbohydrate digestion and absorption in the intestine. - It does not directly improve **insulin sensitivity** or act via the AMPK pathway. - It works by slowing glucose absorption, not by improving cellular insulin response.

Q: A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

They inhibit ovulation. ***They inhibit ovulation*** - Oral contraceptive pills (OCPs) primarily act by suppressing the **hypothalamic-pituitary-ovarian axis**, preventing the surge of **luteinizing hormone (LH)** required for ovulation. - The **estrogen and progestin** components in OCPs provide negative feedback, leading to inconsistent follicular development and the absence of a dominant follicle. *They increase uterine contractility* - OCPs generally **decrease uterine contractility** to prevent implantation, rather than increase it in a way that would expel a pregnancy. - Increased uterine contractility could potentially interfere with implantation, but this is not the primary mechanism of action of OCPs for preventing conception. *They alter the pH of the vagina* - OCPs do **not significantly alter the vaginal pH** as a primary mechanism for preventing pregnancy. - Changes in vaginal pH are more commonly associated with methods like spermicides or natural physiological variations, not hormonal contraception. *They promote the thickening of cervical mucus* - While OCPs do cause the **thickening of cervical mucus**, making it difficult for sperm to penetrate and reach the egg, this is a **secondary mechanism**. - The **primary and most effective mechanism** is the inhibition of ovulation.

Q: What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Inhibit osteoclast activity. ***Inhibit osteoclast activity*** - Bisphosphonates are analogs of **pyrophosphate** that bind to **hydroxyapatite crystals** in the bone matrix. - Once internalized by osteoclasts during bone resorption, they disrupt the **mevalonate pathway**, leading to osteoclast apoptosis and reduced bone breakdown. *Enhance calcium absorption* - This is primarily the role of **Vitamin D**, which promotes calcium uptake from the gut. - Bisphosphonates do not directly affect **intestinal calcium absorption**. *Stimulate osteoblast activity* - Drugs like **teriparatide** (a parathyroid hormone analog) are known to stimulate osteoblast function and new bone formation. - Bisphosphonates primarily act to reduce bone resorption, not directly stimulate **bone formation**. *Increase parathyroid hormone levels* - **Parathyroid hormone (PTH)** plays a key role in calcium homeostasis, and chronically elevated PTH can lead to bone resorption. - Bisphosphonates do not increase PTH levels; instead, they work independently to strengthen bone.

Q: A patient with osteoporosis is given a drug that acts as a monoclonal antibody against RANK ligand (RANKL). Which drug is appropriate?

Denosumab. ***Denosumab*** - **Denosumab** is a **monoclonal antibody** that specifically targets and inhibits **RANKL**. - By binding to **RANKL**, denosumab prevents its interaction with **RANK** on osteoclast precursors and mature osteoclasts, thereby inhibiting osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone density. *Alendronate* - **Alendronate** is a **bisphosphonate**, a class of drugs that inhibit **osteoclast activity** by embedding into the bone matrix and inducing osteoclast apoptosis. - Its mechanism of action is distinct from targeting RANKL. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)**. - It acts as an **estrogen agonist** in bone, helping to prevent bone loss, but its mechanism does not involve direct RANKL inhibition. *Zoledronic acid* - **Zoledronic acid** is also a **bisphosphonate**, similar to alendronate, and is administered intravenously. - It inhibits bone resorption by inducing **osteoclast apoptosis** and interfering with the **mevalonate pathway**, not by blocking RANKL.

Q: Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Pioglitazone. ***Pioglitazone*** - **Pioglitazone** is a **thiazolidinedione (TZD)** that exerts its effects by activating **PPAR-γ** receptors. - Activation of **PPAR-γ** leads to increased **insulin sensitivity** in peripheral tissues and the liver, reducing insulin resistance. *Glibenclamide* - **Glibenclamide** is a **sulfonylurea** that works by stimulating **insulin secretion** from pancreatic **beta cells**. - It binds to the **sulfonylurea receptor 1 (SUR1)** on the **ATP-sensitive potassium channel**, causing depolarization and insulin release, not increased insulin sensitivity. *Metformin* - **Metformin** is a **biguanide** that primarily reduces **hepatic glucose production** and slightly increases peripheral glucose uptake. - Its main mechanism involves activation of **AMP-activated protein kinase (AMPK)**, not **PPAR-γ**. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the digestion and absorption of carbohydrates in the gastrointestinal tract. - It reduces postprandial glucose excursions by interfering with carbohydrate breakdown, rather than affecting insulin sensitivity directly.

Q: What is the first-line drug for osteoporosis in postmenopausal women?

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis due to their proven efficacy in reducing fracture risk by inhibiting osteoclast activity. - They bind to bone mineral and are internalized by osteoclasts, leading to their **apoptosis** and decreased bone resorption. *OCP* - **Oral contraceptives (OCP)** are not used for treating established osteoporosis; they may have a minor protective effect against bone loss in premenopausal women but are not a primary therapeutic agent postmenopause. - OCPs primarily contain **estrogen and/or progestin** and are used for contraception and managing menstrual irregularities. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, especially if there's a concern for breast cancer, but it is typically a second-line option. - Although it mimics estrogen's beneficial effects on bone, it does not have the same overall fracture reduction efficacy as bisphosphonates and can increase the risk of **venous thromboembolism**. *Strontium* - **Strontium ranelate** is an anti-osteoporotic agent that both inhibits bone resorption and promotes bone formation. - Its use has been limited due to concerns about serious side effects, including an increased risk of **cardiovascular events** and **venous thromboembolism**, making it a less favored option compared to bisphosphonates.

Q: Which of the following drugs is used in SIADH?

Tolvaptan. ***Tolvaptan*** - **Tolvaptan** is an **oral vasopressin V2-receptor antagonist** that promotes water excretion without affecting sodium, making it effective for **hyponatremia** associated with SIADH [1]. - It works by blocking the action of **antidiuretic hormone (ADH)** at the renal collecting ducts, increasing free water clearance and thus raising serum sodium levels [1].*Desmopressin* - **Desmopressin** is a synthetic analog of **ADH (vasopressin)**, which acts as a V2 receptor agonist [2]. - It is used to **increase water reabsorption** and is therefore contraindicated in SIADH, where ADH levels are already inappropriately high [1].*Von Willebrand factor* - **Von Willebrand factor** is a protein primarily involved in **hemostasis** and is used to treat **Von Willebrand disease** and **hemophilia A**. - It has no role in the management of SIADH, which is a disorder of water balance.*Terlipressin* - **Terlipressin** is a vasopressin analog that acts as a **V1 receptor agonist**, primarily causing splanchnic vasoconstriction. - It is used to treat **esophageal variceal bleeding** and **hepatorenal syndrome**, but it is not indicated for SIADH.

Q: Raloxifene is known to decrease the risk of which type of cancer?

Breast cancer. ***Breast cancer*** - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen antagonist in breast tissue, thereby reducing the risk of developing **estrogen receptor-positive breast cancer**. - It is FDA-approved for reducing the risk of invasive breast cancer in **postmenopausal women** at high risk. - The **STAR trial** demonstrated raloxifene's efficacy in breast cancer risk reduction, with fewer side effects than tamoxifen. *Cervical cancer* - **Cervical cancer** is primarily caused by persistent infection with **high-risk human papillomaviruses (HPVs)**. - **Raloxifene** has no known protective effect against **HPV infection** or the development of cervical dysplasia or cancer. *Endometrial cancer* - Unlike breast tissue, **raloxifene** acts as an estrogen antagonist in the **endometrium** and does **not increase** endometrial cancer risk (unlike tamoxifen). - However, it does **not decrease** endometrial cancer risk either; it maintains a neutral effect on endometrial tissue. *Ovarian cancer* - **Ovarian cancer** is a complex disease with various risk factors, but **raloxifene** does not significantly impact its incidence. - While some SERMs have shown varying effects on gynecological cancers, **raloxifene** is not indicated or known to prevent **ovarian cancer**.

Question 1

A 50-year-old male with type 2 diabetes is prescribed a new medication to manage his condition. Which drug reduces postprandial hyperglycemia without increasing insulin levels?

Accepted Answer

Voglibose

Answer

Metformin

Answer

Glibenclamide

Answer

Pioglitazone

Question 2

Evaluate the reasons why metformin is contraindicated in patients with severe renal impairment.

Accepted Answer

Risk of lactic acidosis

Answer

Increased risk of hypoglycemia

Answer

Potential for liver toxicity

Answer

Potential for reduced drug efficacy in patients with renal impairment

Question 3

Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Accepted Answer

Metformin

Answer

Glibenclamide

Answer

Pioglitazone

Answer

Acarbose

Question 4

A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

Accepted Answer

They inhibit ovulation

Answer

They increase uterine contractility

Answer

They alter the pH of the vagina

Answer

They promote the thickening of cervical mucus

Question 5

What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Accepted Answer

Inhibit osteoclast activity

Answer

Enhance calcium absorption

Answer

Stimulate osteoblast activity

Answer

Increase parathyroid hormone levels

Question 6

A patient with osteoporosis is given a drug that acts as a monoclonal antibody against RANK ligand (RANKL). Which drug is appropriate?

Accepted Answer

Denosumab

Answer

Alendronate

Answer

Raloxifene

Answer

Zoledronic acid

Question 7

Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Accepted Answer

Pioglitazone

Answer

Glibenclamide

Answer

Metformin

Answer

Acarbose

Question 8

What is the first-line drug for osteoporosis in postmenopausal women?

Accepted Answer

Bisphosphonates

Answer

OCP

Answer

Raloxifene

Answer

Strontium

Question 9

Which of the following drugs is used in SIADH?

Accepted Answer

Tolvaptan

Answer

Desmopressin

Answer

Von Willebrand factor

Answer

Terlipressin

Question 10

Raloxifene is known to decrease the risk of which type of cancer?

Accepted Answer

Breast cancer

Answer

Cervical cancer

Answer

Ovarian cancer

Answer

Endometrial cancer

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?